Patients with severe asthma are now able to choose where they receive treatment - at home or via a healthcare professional.
Wheezo will become an absolute necessity for home monitoring of severe asthma if patients choose to self administer.
And the data/info wheezo is capturing will be most important to physicians and better understand how patients are monitoring their asthma.
https://www.healthindustryhub.com.au/pharmaceutical-news-trends/gsks-targeted-therapy-for-asthma-gains-pbs-listing-for-self-administration-delivery/
Cheers
Biological - PBS listing
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.4¢ |
Change
0.001(3.03%) |
Mkt cap ! $36.03M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.5¢ | 3.3¢ | $7.186K | 213.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38701 | 3.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.5¢ | 201558 | 3 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
3.2¢ |
Change
0.001 ( 3.03 %) |
||||
| Open | High | Low | Volume | ||
| 3.5¢ | 3.5¢ | 3.2¢ | 49831 | ||
| Last updated 11.52am 26/04/2024 ? | |||||
| RSH (ASX) Chart |